TY - JOUR
T1 - Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata
AU - Palella, Frank J.
AU - Deloria-Knoll, Maria
AU - Chmiel, Joan S.
AU - Moorman, Anne C.
AU - Wood, Kathleen C.
AU - Greenberg, Alan E.
AU - Holmberg, Scott D.
PY - 2003/4/15
Y1 - 2003/4/15
N2 - Background: Optimal timing of antiretroviral therapy (ART) initiation for HIV-infected persons remains unclear. Objective: To assess survival benefit of initiating ART at different CD4+ cell counts. Design: Prospective observational study. Setting: U.S. clinics in the HIV Outpatient Study (HOPS). Patients: HIV-infected patients with CD4+ cell counts, plasma HIV RNA viral load, and ART use recorded from January 1994 through March 2002. Measurements: Before initiation of ART, patients were grouped by their CD4+ cell counts into three subgroups: 0.201 to 0.350 × 109 cells/L (n = 399), 0.351 to 0.500 × 109 cells/L (n = 327), and 0.501 to 0.750 × 109 cells/L (n = 122). We compared mortality rates for each CD4 + subgroup among patients who initiated ART and patients who delayed ART until reaching a lower CD4+ subgroup. Results: Mortality rates for 340 patients who initiated ART and 59 who delayed ART in the CD4+ subgroup of 0.201 to 0.350 × 109 cells/L were 15.4 and 56.4 deaths per 1000 person-years, respectively (rate ratio, 0.27 [95% CI, 0.14 to 0.55]; P < 0.001). For the CD4+ subgroup of 0.351 to 0.500 × 10 9 cells/L, mortality rates for 240 patients who initiated ART and 887 who delayed ART were 10.0 and 16.6 deaths per 1000 person-years, respectively (rate ratio, 0.61 [CI, 0.22 to 1.67]; P = 0.17). For the CD4 + subgroup of 0.501 to 0.750 × 109 cells/L, mortality rates in 55 patients who initiated ART and 67 who delayed ART were 7. 5 and 3.1 deaths per 1000 person-years, respectively (rate ratio, 1.20 [CI, 0. 17 to 8.53]; P > 0.2). Patients in the 0.201 to 0.350 x 109 cells/L and 0. 351 to 0.500 × 109 cells/L CD4+ sub-groups who initiated ART were more likely than those who delayed ART to achieve an undetectable HIV viral load (P = 0.03 and 0.04, respectively). Conclusions: Among HIV-infected persons with CD4+ cell counts of 0.201 to 0.350 × 109 cells/L, initiating ART is associated with reduced mortality compared with delaying such therapy. Survival benefits of earlier ART initiation (at CD4+ cell counts of 0.351 to 0.500 × 10 9 cells/L) are possible.
AB - Background: Optimal timing of antiretroviral therapy (ART) initiation for HIV-infected persons remains unclear. Objective: To assess survival benefit of initiating ART at different CD4+ cell counts. Design: Prospective observational study. Setting: U.S. clinics in the HIV Outpatient Study (HOPS). Patients: HIV-infected patients with CD4+ cell counts, plasma HIV RNA viral load, and ART use recorded from January 1994 through March 2002. Measurements: Before initiation of ART, patients were grouped by their CD4+ cell counts into three subgroups: 0.201 to 0.350 × 109 cells/L (n = 399), 0.351 to 0.500 × 109 cells/L (n = 327), and 0.501 to 0.750 × 109 cells/L (n = 122). We compared mortality rates for each CD4 + subgroup among patients who initiated ART and patients who delayed ART until reaching a lower CD4+ subgroup. Results: Mortality rates for 340 patients who initiated ART and 59 who delayed ART in the CD4+ subgroup of 0.201 to 0.350 × 109 cells/L were 15.4 and 56.4 deaths per 1000 person-years, respectively (rate ratio, 0.27 [95% CI, 0.14 to 0.55]; P < 0.001). For the CD4+ subgroup of 0.351 to 0.500 × 10 9 cells/L, mortality rates for 240 patients who initiated ART and 887 who delayed ART were 10.0 and 16.6 deaths per 1000 person-years, respectively (rate ratio, 0.61 [CI, 0.22 to 1.67]; P = 0.17). For the CD4 + subgroup of 0.501 to 0.750 × 109 cells/L, mortality rates in 55 patients who initiated ART and 67 who delayed ART were 7. 5 and 3.1 deaths per 1000 person-years, respectively (rate ratio, 1.20 [CI, 0. 17 to 8.53]; P > 0.2). Patients in the 0.201 to 0.350 x 109 cells/L and 0. 351 to 0.500 × 109 cells/L CD4+ sub-groups who initiated ART were more likely than those who delayed ART to achieve an undetectable HIV viral load (P = 0.03 and 0.04, respectively). Conclusions: Among HIV-infected persons with CD4+ cell counts of 0.201 to 0.350 × 109 cells/L, initiating ART is associated with reduced mortality compared with delaying such therapy. Survival benefits of earlier ART initiation (at CD4+ cell counts of 0.351 to 0.500 × 10 9 cells/L) are possible.
UR - http://www.scopus.com/inward/record.url?scp=0038662719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038662719&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-138-8-200304150-00007
DO - 10.7326/0003-4819-138-8-200304150-00007
M3 - Article
C2 - 12693883
AN - SCOPUS:0038662719
SN - 0003-4819
VL - 138
SP - 620-626+I28
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 8
ER -